Login to Your Account

Medivation, Pfizer End Deal

Dimebon Alzheimer's Results Expected, Still Disappointing

By Catherine Shaffer
BioWorld Today Contributing Writer

Wednesday, January 18, 2012

Although expected, results from Medivation Inc.'s Phase III CONCERT trial of Dimebon (laterpirdine) in Alzheimer's disease were still a letdown.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription